Europe | Science and Enterprise

A biotechnology company is developing treatments for cancer and other diseases using Crispr gene editing delivered… https://t.co/cZ13M2gPJk
about 19 hours ago
New post on Science and Enterprise: Biotech Creating More Efficient Crispr Therapies https://t.co/JAfb7hBMoH #Science #Business
about 19 hours ago
I have a Mode joke. It was a Moderna joke, but a messenger lost the RNA.
about 2 days ago
Behind the scenes, CEPI and BARDA were funding vaccine development and covering manufacturing costs. They helped ge… https://t.co/4F5vMbVsrK
about 3 days ago
A YouGov survey taken earlier this month indicates the U.S. public largely supports rejoining the Paris climate agr… https://t.co/eJd2v8G7K8
about 3 days ago

Biotech Creating More Efficient Crispr Therapies

By Alan, on November 30th, 2020%

A biotechnology company is developing treatments for cancer and other diseases using Crispr gene editing delivered with more efficient synthetic proteins. . . . → Read More: Biotech Creating More Efficient Crispr Therapies

Stem Cell Respiratory Therapy Licensed in $1.4B Deal

By Alan, on November 20th, 2020%

Global drug maker Novartis is acquiring a stem cell-based treatment for a serious respiratory disease associated with Covid-19 infections. . . . → Read More: Stem Cell Respiratory Therapy Licensed in $1.4B Deal

Tech, Genomics Companies Form DNA Storage Alliance

By Alan, on November 13th, 2020%

Four companies from the computer technology and genomics industries are starting a coalition to advance DNA as a data storage medium. . . . → Read More: Tech, Genomics Companies Form DNA Storage Alliance

Gene-Editing Enzyme Start-Up Gains $65M

By Alan, on November 12th, 2020%

A new company creating engineered enzymes for genome editing therapeutics is raising $65 million in its first venture funding round. . . . → Read More: Gene-Editing Enzyme Start-Up Gains $65M

Oral Drug Delivery Company Acquired in $1.8B Deal

By Alan, on November 6th, 2020%

Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk. . . . → Read More: Oral Drug Delivery Company Acquired in $1.8B Deal

Crispr Therapy Shown to Help Blood Disorder Patients

By Alan, on November 4th, 2020%

Interim clinical trial results show an experimental treatment derived from gene-edited stem cells relieves symptoms in patients with severe inherited blood diseases. . . . → Read More: Crispr Therapy Shown to Help Blood Disorder Patients

Trial Shows Covid-19 Vaccine Safety, Immune Response

By Alan, on November 3rd, 2020%

First results from an early-stage clinical trial show an RNA-based vaccine to prevent Covid-19 infections is safe and produces a complex immune response. . . . → Read More: Trial Shows Covid-19 Vaccine Safety, Immune Response

200M Covid-19 Vaccine Doses Donated to Int’l Effort

By Alan, on October 28th, 2020%

Sanofi and GlaxoSmithKline are offering 200 million doses of their Covid-19 vaccine for a project devoted to making vaccines equitably available worldwide. . . . → Read More: 200M Covid-19 Vaccine Doses Donated to Int’l Effort

Novartis Gains Synthetic Protein Therapies for Covid-19

By Alan, on October 28th, 2020%

Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components. . . . → Read More: Novartis Gains Synthetic Protein Therapies for Covid-19

Bayer Gains Gene Therapy Biotech in $4B Deal

By Alan, on October 26th, 2020%

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise